title: Circulating resistin levels and obesity-related cancer risk: A meta-analysis.
abstract: Resistin levels have been reported to be abnormal in obesity-related cancer patients with epidemiological studies yielding inconsistent results. Therefore, a meta-analysis was performed to assess the association between blood resistin levels and obesity-related cancer risk. A total of 13 studies were included for pooling ORs analysis. High resistin levels were found in cancer patients (OR= 1.20, 95% CI= 1.10-1.30). After excluding one study primarily contributing to between-study heterogeneity, the association between resistin levels and cancer risk was still significant (OR=1.18, 95% CI = 1.09-1.28). Stratification analysis found resistin levels were not associated with cancer risk in prospective studies. Meta-regression analysis identified factors such as geographic area, detection assay, or study design as confounders to between-study variance. The result of 18 studies of pooling measures on SMD analysis was that high resistin levels were associated with increased cancer risk (SMD = 0.94, 95% CI = 0.63-1.25), but not in the pooling SMD analysis of prospective studies. Except for the studies identified as major contributors to heterogeneity by Galbraith plot, resistin levels were still higher in cancer patients (SMD = 0.75, 95% CI = 0.63-0.87) in retrospective studies. Meta-regression analysis found factors, such as geographic area, BMI-match, size, and quality score, could account for 66.7% between-study variance in pooling SMD analysis of retrospective studies. Publication bias was not found in pooling ORs analysis. Our findings indicated high resistin levels were associated with increased obesity-related cancer risk. However, it may not be a predictor.
authors: Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, P. R. China.|Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, P. R. China.|Hunan Province Cooperation Innovation Center for Molecular Target New Drug Study, Hengyang, P. R. China.
authors: Wei-Jing
authors: WJ
authors: Gong
authors: Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, P. R. China.|Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, P. R. China.
authors: Wei
authors: W
authors: Zheng
authors: Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, P. R. China.|Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, P. R. China.
authors: Ling
authors: L
authors: Xiao
authors: Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, P. R. China.|Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, P. R. China.
authors: Li-Ming
authors: LM
authors: Tan
authors: Department of Otolaryngology, Xiangya Hospital, Central South University, Changsha, P.R. China.
authors: Jian
authors: J
authors: Song
authors: Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, P.R. China.
authors: Xiang-Ping
authors: XP
authors: Li
authors: Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, P. R. China.|Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, P. R. China.
authors: Di
authors: D
authors: Xiao
authors: Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, P. R. China.|Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, P. R. China.
authors: Jia-Jia
authors: JJ
authors: Cui
authors: Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, P. R. China.|Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, P. R. China.
authors: Xi
authors: X
authors: Li
authors: Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, P. R. China.|Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, P. R. China.
authors: Hong-Hao
authors: HH
authors: Zhou
authors: Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, P. R. China.|Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, P. R. China.|Hunan Province Cooperation Innovation Center for Molecular Target New Drug Study, Hengyang, P. R. China.
authors: Ji-Ye
authors: JY
authors: Yin
authors: Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, P. R. China.|Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, P. R. China.|Hunan Province Cooperation Innovation Center for Molecular Target New Drug Study, Hengyang, P. R. China.
authors: Zhao-Qian
authors: ZQ
authors: Liu
mesh_terms: D006801:Humans; D015999:Multivariate Analysis; D009369:Neoplasms / Q000097:blood* / Q000150:complications*; D009765:Obesity / Q000097:blood* / Q000150:complications*; D016017:Odds Ratio; D011446:Prospective Studies; D012044:Regression Analysis; D052243:Resistin / Q000097:blood*; D012189:Retrospective Studies; D012307:Risk Factors
chemical_list: C499624:RETN protein, human; D052243:Resistin
keywords: circulating resistin levels; meta-analysis; obesity-related cancer